Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability

Inclusion Criteria: * Informed consent form obtained before any study-related activity. Study-related activities are any procedure that would not be performed during the normal treatment of the patient. * All study subjects must be women diagnosed with type 2 diabetes based on current guidelines of Sociedade Brasileira de Diabetes (SBD - Brazilian Society of Diabetes) and/or American Society of Diabetes (ADA) and they should have all the following criteria: * Age ≥ 40 years old. * HbA1c ≥ 6.5% at randomization. * Menopause defined as: * Absence of menstruation for at least 12 months in patients with an intact uterus, or * FSH level greater than 30 mIU/mL in a hysterectomized patient and/or, * FSH level greater than 30 mIU/mL in a patient with surgical menopause. Exclusion Criteria: * Acute vascular event (cardiac, cerebral or peripheral) for at least 2 months of randomization. * Patient on chronic dialysis and/or renal transplantation and/or serum creatinine \> 1.5 mg/dL. * Patients with HIV, severe autoimmune disease or chronic treatment with oral steroids (\> 30 consecutive days). * Current or previous treatment (within 6 months) with incretin (DPP-IV inhibitor or GLP-1 analog) within 6 months prior to randomization. * Current or previous treatment with pioglitazone or rosiglitazone within 12 months prior to randomization. * Sustained arterial hypertension \> 180/100 mm Hg. * Body mass index (BMI) \> 50 kg/m². * HbA1c ≥ 9,5% at randomization. * Transaminases (AST (SGOT) and ALT (SGPT)) \> 2.5 x upper limit of normal. * Chronic liver disease or alcoholic liver disease. * LDL-cholesterol \> 250 mg/dL (\> 6.48 mmol/L). * Triglycerides \> 1000 mg/dL (\> 11.3 mmol/L). * HDL-cholesterol \< 25 mg/dL (\< 0.64 mmol/L). * Levels of 25-OH-vitamin D \< 20ng/mL at randomization * Abnormal levels of PTH, cortisol, IGF-1 or GH at randomization * Prescription of any investigational medication within one year before the screening visit (visit 1), unless there is a direct benefit to the study subject, at the discretion of the investigator. * History of previous fracture * Pregnant or breastfeeding patients. * Previous participation on this study. * Individuals at risk for poor adherence to the protocol or medication. * Any condition that makes the patient unable to complete the study within 12 months.